|
Conference/Events
| ShowHide Related Items >><< - 01/06/21
- AmerisourceBergen to acquire Alliance Healthcare from Walgreens for $6.5B
- 11/09/20
- AmerisourceBergen names Dr. Lonie Haynes as Chief Diversity & Inclusion Office
- 11/06/20
- AmerisourceBergen reaches agreement with CDC over pharmacy vaccine access
- 11/05/20
- AmerisourceBergen sees FY21 CapEx ~$400M
- 02/08/21
- Point72 Asset Management reports 5.0% passive stake in Affimed N.V.
- 02/03/21
- Affimed N.V. announces pact with Roche to study AFM24/atezolizumab combo
- 01/07/21
- Affimed N.V. provides pipeline and business update
- 11/19/20
- Affimed announces publication of results from study of ICE with Keytruda
- $241.61 /
-11.92 (-4.70%) - 02/24/21
- Amedisys promotes Christopher Gerard to COO, Scott Ginn to CFO
- 01/05/21
- Amedisys, Option Care Health collaborate on COVID therapy access model
- 12/23/20
- Amedisys announces up to $100M share repurchase plan
- 03/03/21
- U.S. District Court rules in AstraZeneca's favor in Symbicort patent litigation
- 03/02/21
- AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
- 03/01/21
- FibroGen, AstraZeneca report FDA to hold AdCom meeting to review roxadustat NDA
- 02/26/21
- Amgen, AstraZeneca report 'positive' results from NAVIGATOR Phase 3 trial
- 02/25/21
- Pfizer, BioNTech to evaluate safety of third dose of COVID-19 vaccine
- 02/22/21
- Amyris announces pre-clinical results for COVID RNA vaccine platform
- 02/19/21
- Pfizer, BioNTech submit COVID-19 vaccine stability data to the FDA
- 02/18/21
- Pfizer, BioNTech start trial to evaluate COVID-19 vaccine in pregnant women
- 02/12/21
- Carlisle names Kelly P. Kamienski as Controller
- 02/02/21
- Carlisle announces additional buyback of 5M shares of common stock
- 02/05/21
- CureVac enters pact with UK Government to develop SARS-CoV-2 variant vaccine
- 02/04/21
- CureVac expands CV8102 cancer program to advanced melanoma
- 02/03/21
- CureVac, GSK in pact to jointly develop mRNA vaccines for COVID-19
- 01/07/21
- Bayer signs collaboration, services agreement with CureVac for COVID-19 vaccine
- 02/10/21
- Model N discloses J&J agreed to transition to its Revenue Cloud for Life Science
- 01/19/21
- CytoSorb approved in Korea for all EU approved indications
- 02/10/21
- Galapagos, Gilead discontinue Phase 3 ISABELA trials
- 02/10/21
- Gilead, Galapagos discontinue ISABELA Phase 3 trials in IPF
- 01/21/21
- Galapagos announces NICE recommendation for Jyseleca on NHS
- 12/15/20
- Galapagos to assume development, manufacturing, other rights for Jyseleca
- 01/08/21
- Galecto appoints Anne Prener to board of directors
- 11/30/20
- Galecto announces publication of GB0139 Phase 2a IPF results
- 03/03/21
- Vir, GSK: DSMB recommends VIR-7831 arm of ACTIV-3 trial be closed to enrollment
- 03/02/21
- Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX
- 02/24/21
- J&J's Janssen announces submission of sNDA to FDA for expanded Cabenuva use
- 02/24/21
- ViiV Healthcare submits sNDA to FDA for HIV treatment Cabenuva
- 01/05/21
- Inventiva announces Phase 3 lanifibranor trial details
- 12/07/20
- Inventiva announces journal publication on effect of lanifibranor in ACLD
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 03/02/21
- Fusion Pharmaceuticals to acquire Ipsen's IP, assets related to IPN-1087
- 02/26/21
- Exelixis: Ipsen receives positive CHMP opinion for CABOMETYX/OPDIVO combo
- 02/22/21
- Ipsen to announce new data from CLARINET FORTE study at ENETS Conference
- 11/30/20
- Ipsen announces Fast Track designation for irinotecan liposome injection
- 03/01/21
- Lantheus announces publication of PyL results from pivotal studies
- 01/12/21
- Lantheus announces submission of DMF for NM-01 in the U.S.
- 12/09/20
- Lantheus reports acceptance, priority review of New Drug Application for PyLTM
- 12/09/20
- Lantheus enters strategic collaboration with Point Biopharma to use PET
- 01/19/21
- NOV Inc. falls -6.5%
- 12/21/20
- National Oilwell to adopt new corporate name 'NOV Inc.'
- 11/18/20
- National Oilwell, NexTier Oilfield partner on field test of electric frac system
- 03/02/21
- Novartis shareholders approve 1.7% increase in dividend to CHF 3.00 per share
- 03/01/21
- Homology Medicines regains worldwide rights to ophthalmology program
- 02/17/21
- Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation
- 02/16/21
- Novartis reports Entresto granted expanded indication in chronic heart failure
- 03/03/21
- Philips, Disney partner to enhance Philips Ambient Experience for children
- 03/03/21
- Philips announces 2000th installation of Ambient Experience solution
- 03/02/21
- Acutus Medical appoints Duane Wilder as CCO
- 03/02/21
- Philips partners with DiA Imaging Analysis to enhance ultrasound
- 02/22/21
- Regeneron announces third FDA approval for PD-1 inhibitor Libtayo
- 02/22/21
- Sanofi, GSK initiate Phase 2 study of COVID-19 vaccine candidate
- 02/12/21
- Sanofi offers to acquire Kiadis Pharma shares for EUR 5.45 per share in cash
- 02/12/21
- Regeneron, Sanofi announce results from Libtayo comparative study published
TAK Takeda Pharmaceutical - 03/03/21
- Takeda secures rights to soticlestat from Ovid Therapeutics for $196M upfront
- 02/26/21
- Novavax, Takeda finalize license agreement for COVID-19 vaccine in Japan
- 02/26/21
- Takeda to divest type 2 diabetes portfolio to Teijin Pharma for JPY 133B
- 02/24/21
- Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan
- 12/15/20
- Zealand Pharma: Dasiglucagon did not meet primary endpoint in Phase 3 trial
- 12/15/20
- Zealand Pharma announces data from Phase 3 dasiglucagon in CHI trial
- 11/20/20
- Zealand Pharma increases share capital following exercise of employee warrants
- 02/09/21 Mizuho
- AmerisourceBergen price target raised to $114 from $104 at Mizuho
- 02/08/21 Cowen
- AmerisourceBergen price target raised to $150 from $145 at Cowen
- 02/04/21 Evercore ISI
- AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
- 02/04/21 Evercore ISI
- AmerisourceBergen upgraded to Outperform from In Line at Evercore ISI
- $241.61 /
-11.92 (-4.70%) - 02/23/21 Benchmark
- Amedisys price target raised to $325 from $275 at Benchmark
- 02/08/21 Deutsche Bank
- Amedisys price target raised to $340 from $275 at Deutsche Bank
- 01/05/21 Truist
- Amedisys price target raised to $325 from $280 at Truist
- 11/03/20 Barclays
- Amedisys price target raised to $298 from $290 at Barclays
- 02/25/21
- Fly Intel: Top five analyst upgrades
- 02/25/21 UBS
- AstraZeneca upgraded to Buy from Neutral at UBS
- 02/04/21 Piper Sandler
- Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
- 02/01/21 BofA
- BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
- 02/23/21 B. Riley Securities
- B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 01/29/21 Piper Sandler
- Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/26/21 Longbow
- Carlisle price target raised to $160 from $150 at Longbow
- 01/08/21 Oppenheimer
- Carlisle price target raised to $175 from $160 at Oppenheimer
- 11/13/20
- Carlisle cut to Hold at Loop Capital on valuation
- 11/13/20 Loop Capital
- Carlisle downgraded to Hold from Buy at Loop Capital
- 01/07/21 Morgan Stanley
- CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
- 12/10/20 Credit Suisse
- CureVac downgraded to Underperform on rising valuation at Credit Suisse
- 12/10/20 Credit Suisse
- CureVac downgraded to Underperform from Neutral at Credit Suisse
- 11/02/20 Piper Sandler
- CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
- 03/02/21 Berenberg
- Fresenius Medical price target lowered to EUR 79.50 from EUR 80.40 at Berenberg
- 02/26/21 JPMorgan
- Fresenius Medical price target raised to EUR 52.40 from EUR 51.10 at JPMorgan
- 02/24/21 Truist
- Fresenius Medical cut to Hold at Truist on more difficult operating backdrop
- 02/24/21 Truist
- Fresenius Medical downgraded to Hold from Buy at Truist
- 03/02/21 Barclays
- Galapagos price target lowered to EUR 69 from EUR 85.50 at Barclays
- 02/23/21 BofA
- Galapagos upgraded to Neutral from Underperform at BofA
- 02/23/21 BofA
- Galapagos upgraded to Neutral from Underperform at BofA
- 02/19/21 Raymond James
- Raymond James upgrades 'heavily discounted' Galapagos to Outperform
- 11/23/20 SVB Leerink
- SVB Leerink bullish on Galecto, initiates with an Outperform
- 11/23/20 SVB Leerink
- Galecto initiated with an Outperform at SVB Leerink
- 11/23/20 Credit Suisse
- Galecto initiated with an Outperform at Credit Suisse
- 11/23/20 BofA
- Galecto initiated with a Buy at BofA
- 03/03/21 H.C. Wainwright
- Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
- 02/12/21 Morgan Stanley
- GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley
- 02/11/21 Berenberg
- GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg
- 02/09/21 JPMorgan
- GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
- 02/16/21 Barclays
- Ipsen price target lowered to EUR 89 from EUR 96 at Barclays
- 01/14/21 Societe Generale
- Ipsen upgraded to Buy from Hold at Societe Generale
- 12/08/20 Morgan Stanley
- Ipsen downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/04/20 BofA
- Ipsen downgraded to Neutral from Buy at BofA
- 02/01/21
- Fly Intel: Top five analyst initiations
- 02/01/21 SVB Leerink
- SVB Leerink bullish on Lantheus, initiates with an Outperform
- 02/01/21 SVB Leerink
- Lantheus initiated with an Outperform at SVB Leerink
- 12/29/20 Credit Suisse
- Lantheus price target lowered to $14 from $16 at Credit Suisse
- 01/21/21 Susquehanna
- NOV Inc. price target lowered to $17 from $18 at Susquehanna
- 01/21/21 Wells Fargo
- NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
- 01/21/21 Wells Fargo
- NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
- 01/12/21 Citi
- NOV Inc. upgraded to Buy from Neutral at Citi
- 03/01/21 Oppenheimer
- Homology Medicines loses potential source of upside, says Oppenheimer
- 02/02/21 Morgan Stanley
- Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
- 02/01/21 Truist
- iRhythm price target lowered to $220 from $265 at Truist
- 02/01/21 Cowen
- Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
- 01/26/21 Credit Suisse
- Philips price target raised to EUR 45 from EUR 41 at Credit Suisse
- 01/26/21 JPMorgan
- Philips price target raised to EUR 44.90 from EUR 44 at JPMorgan
- 01/26/21 UBS
- Philips price target raised to EUR 54 from EUR 51 at UBS
- 01/25/21 Morgan Stanley
- iRhythm price target raised to $288 from $227 at Morgan Stanley
- 02/23/21 BofA
- BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
- 02/10/21 Morgan Stanley
- Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
- 01/19/21 UBS
- Sanofi price target lowered to EUR 99 from EUR 100 at UBS
TAK Takeda Pharmaceutical - 03/03/21 RBC Capital
- Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
- 01/29/21 Morgan Stanley
- Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
- 12/29/20 Needham
- Needham names Phathom Pharmaceuticals Top Pick for 2021
- 12/15/20 Needham
- Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
- 03/10/20 Morgan Stanley
- Zealand Pharma EPS estimates cut at Morgan Stanley
- 02/04/21
- AmerisourceBergen raises FY21 adjusted EPS view to $8.40-$8.60 from $8.25-$8.50
- 02/04/21
- AmerisourceBergen reports Q1 adjusted EPS $2.18, consensus $1.94
- 02/03/21
- Notable companies reporting before tomorrow's open
- 02/03/21
- Notable companies reporting before tomorrow's open
- $241.61 /
-11.92 (-4.70%) - 02/24/21
- Amedisys sees FY21 adjusted EPS $6.25-$6.47, consensus $6.31
- 02/24/21
- Amedisys reports Q4 adjusted EPS $1.49, consensus $1.47
- 10/28/20
- Amedisys sees FY20 EPS $6.02- $6.08, consensus $4.98
- 10/28/20
- Amedisys reports Q3 EPS $2.24, consensus $1.28
- 02/11/21
- AstraZeneca sees FY21 core EPS $4.75-$5.00
- 02/11/21
- AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 02/04/21
- Carlisle reports Q4 EPS $1.57, consensus $1.16
- 10/20/20
- Carlisle reports Q3 EPS $1.87, consensus $1.68
- 02/18/21
- Galapagos reports FY 20 EUR 530M versus EUR 886M in 2019
- 12/11/20
- Galecto reports Q3 EPS ($55.25) vs. ($21.18) last year
- 02/03/21
- GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 02/25/21
- Lantheus sees Q1 EPS (3c) to 0c, consensus 2c
- 02/25/21
- Lantheus reports Q EPS 7c, consensus 1c
- 11/05/20
- Lantheus reports Q3 adj. EPS 4c, consensus 1c
- 02/04/21
- NOV Inc. reports Q4 EPS (90c), consensus (19c)
- 01/19/21
- NOV lowers Q4 revenue view to $1.33B, consensus $1.36B
- 10/26/20
- National Oilwell reports Q3 EPS (14c), consensus (10c)
- 01/26/21
- Novartis sees 2021 core operating income to grow mid single digit
- 01/26/21
- Novartis reports Q4 core EPS $1.34, consensus $1.36
- 11/05/20
- Xoma reports Q3 EPS (10c), consensus (21c)
- 10/27/20
- Novartis raises FY20 core operating income growth outlook
- 01/25/21
- Philips reports Q4 adjusted EPS EUR 0.94 vs. EUR 0.83 last year
- 10/19/20
- Philips reports Q3 adj. EPS EUR 0.60 vs. EUR 0.46 last year
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 11/12/20
- Zealand Pharma expects 2020 revenue for V-Go sales DKK150M-DKK175M
- 11/12/20
- Zealand Pharma reports Q3 revenue DKK56.5M vs. DKK9.9M last year
|